OIRA Conclusion of EO 12866 Regulatory Review

RIN: 0938-AT91         View EO 12866 Meetings	Received Date: 06/20/2019
Title: International Pricing Index Model For Medicare Part B Drugs (CMS-5528-P)
Agency/Subagency: HHS / CMS	Stage: Interim Final Rule
Concluded Action: Consistent with Change	Concluded Date: 11/19/2020
Legal Deadline: None	Economically Significant: Yes
Publication Date: 11/27/2020	Unfunded Mandates: No
Major: Yes	Related To Homeland Security: No
Regulatory Flexibility Analysis Required: Yes	Small Entities Affected: Businesses
Federalism Implications: No	Affordable Care Act [Pub. L. 111-148 & 111-152]: No
International Impacts: Yes	Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]: No
Pandemic Response: No